This can help regulate blood sugar levels and prevent feeling extremely hungry
Who can be a good candidate for GLP-1
In the STEP trials, semaglutide 2.4 mg weekly showed average weight reductions of 1215% of body weight over 68 weeks, whilst in the SCALE trials, liraglutide 3 mg daily typically produced 58% weight loss
Its important to note that the active ingredient in Zepbound, tirzepatide, also operates via the GLP-1 pathway, suggesting a similar risk profile to other GLP-1 agonists
These may present with respiratory symptoms including wheeze, throat tightness, or difficulty breathing, often accompanied by skin rash, itching, or facial swelling
Compounding pharmacies remain regulated under the FDA Modernization Act (FDAMA) Section 503A, which permits licensed facilities to prepare customized medications when commercially unavailable or when patients need dose adjustments